- Home
- WBX vs PROK Comparison
WBX vs PROK Comparison
Compare WBX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WBX
- PROK
- Stock Information
- Founded
- WBX 2015
- PROK 2015
- Country
- WBX Spain
- PROK United States
- Employees
- WBX N/A
- PROK N/A
- Industry
- WBX Industrial Specialties
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WBX Consumer Discretionary
- PROK Health Care
- Exchange
- WBX Nasdaq
- PROK Nasdaq
- Market Cap
- WBX 85.1M
- PROK 85.5M
- IPO Year
- WBX N/A
- PROK N/A
- Fundamental
- Price
- WBX $5.93
- PROK $3.27
- Analyst Decision
- WBX Buy
- PROK Buy
- Analyst Count
- WBX 3
- PROK 5
- Target Price
- WBX $14.33
- PROK $6.25
- AVG Volume (30 Days)
- WBX 18.7K
- PROK 37.1M
- Earning Date
- WBX 07-31-2025
- PROK 08-08-2025
- Dividend Yield
- WBX N/A
- PROK N/A
- EPS Growth
- WBX N/A
- PROK N/A
- EPS
- WBX N/A
- PROK N/A
- Revenue
- WBX $171,352,140.00
- PROK $306,000.00
- Revenue This Year
- WBX N/A
- PROK $85.21
- Revenue Next Year
- WBX $44.10
- PROK N/A
- P/E Ratio
- WBX N/A
- PROK N/A
- Revenue Growth
- WBX 3.75
- PROK N/A
- 52 Week Low
- WBX $4.60
- PROK $0.46
- 52 Week High
- WBX $32.80
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- WBX 83.14
- PROK 62.08
- Support Level
- WBX $5.92
- PROK $3.17
- Resistance Level
- WBX $6.25
- PROK $4.05
- Average True Range (ATR)
- WBX 0.26
- PROK 1.00
- MACD
- WBX 0.20
- PROK 0.13
- Stochastic Oscillator
- WBX 91.95
- PROK 43.10
About WBX Wallbox N.V.
Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.